3874 results about "Urology" patented technology

This disclosure relates to a method of treating depression and / or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

The invention belongs to the technical field of biological medicines, and particularly relates to a composition for treating male erectile dysfunction and application thereof. The oyster polypeptide is prepared by enzymolysis of oyster protein, can effectively promote proliferation of testicular interstitial cells, enhance and improve sexual desire and improve sexual behavior, has certain clinical application value, has the advantages of simple preparation, easy absorption and the like, and is easy to popularize and apply.

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

Disclosed herein are apparatuses, systems, kits, and methods for treating skin, such as skin tightening or for treating diseases, disorders, and conditions that would benefit from tissue area or volume reduction, skin restoration, skin tightening, skin lifting, and / or skin repositioning and / or for generally improving skin function or appearance (e.g., the removal of unwanted skin features or irregularities such as sebaceous glands, sweat glands, hair follicles, necrosis, and fibrosis). Such apparatuses, systems, kits, and methods comprise an apparatus having a handheld main body and a detachably attachable tip comprising one or more needles.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention relates to the technical field of biology, in particular to a swelling hippocampal peptide as well as a preparation method and application thereof. Comprising a polypeptide with an amino acid sequence as shown in SEQ ID NO.1. The hippocampus antioxidative peptide is prepared by adopting an ultrahigh pressure pretreatment and enzymolysis technology, the adopted extraction process is simple in route, and the time and the production cost are effectively saved; an animal model is utilized to prove the antioxidation effect and the effect of improving male reproductive disorder and testis injury of the hippocampal swelling peptide; and on the basis, a novel peptide fragment with high activity, no toxicity and no sensitization is obtained.

The invention provides cubilose peptide and a key preparation method of cubilose peptide maternity cubilose, and the preparation method of the cubilose peptide comprises the following steps: soaking dry cubilose in pure water at 0-4 DEG C according to a material-liquid ratio of 1: 10 for 2 hours, scattering, and spin-drying to obtain soaked cubilose; mixing the soaked cubilose with pure water according to a mass ratio of 1: (15-20), sealing, stewing at 121-123 DEG C for 12-15 minutes, cooling to room temperature, and repeatedly stewing once to obtain fresh stewed cubilose; carrying out an in-vitro digestion experiment on the freshly stewed cubilose, and simulating the digestion process of the freshly stewed cubilose in gastrointestinal tracts to obtain digested cubilose; and centrifuging the digested cubilose to obtain a supernatant, treating the supernatant, carrying out protein sequencing, and carrying out on-line database comparison to screen out peptide fragments with high matching degree and response value greater than 109, thereby obtaining the cubilose peptide. The cubilose peptide can significantly improve the proliferation rate of nerve cells, and provides a cell basis for the development of a nervous system.

This invention relates to a non-invasive predictive kit and method for the progression of benign prostatic hyperplasia (BPH) based on prostatic fluid. The invention provides the application of FGF9 as a non-invasive predictive biomarker for the progression of BPH based on prostatic fluid, wherein the concentration of FGF9 in prostatic fluid serves as an indicator of BPH progression. The invention also provides a method for detecting the concentration of FGF9 in prostatic fluid for non-disease diagnostic purposes. Compared with existing technologies, the non-invasive BPH detection method based on prostatic fluid of this invention has advantages such as non-invasiveness, accuracy, simplicity, practicality, and scalability, and is expected to be widely used in the clinical diagnosis and treatment of prostate diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof for treating thyroid eye disease (TED) are provided herein. Anti-IGF-1R antibodies and compositions described herein can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, by inhibiting the activity of IGF-1R with such antibodies and compositions.

The invention discloses a composition for treating prostatitis and a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 5 to 15 parts of ergothioneine, 10 to 20 parts of cistanche total glycosides, 25 to 45 parts of phytosterol, 450 to 550 parts of pumpkin seed oil, 180 to 250 parts of fructus cannabis oil and 250 to 350 parts of auxiliary materials. Through the synergistic effect of various natural active components, the composition maintains the balance of overall metabolism of a body while reducing inflammation and inhibiting prostate cell proliferation, side effect risks possibly brought by a traditional single-component treatment scheme are avoided, and the composition has higher clinical application potential. The composition disclosed by the invention has a wide market application prospect and popularization value by virtue of good safety and compliance.

Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab. Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment.

The invention provides a polypeptide composition and application thereof in treating male erectile dysfunction. Specifically, the polypeptide composition contains the erectile peptide screened and identified by the invention, and the erectile peptide has good oxidation fatigue resistance, can effectively promote penile erection, improve testosterone level and effectively treat erectile dysfunction, and has wide application prospects.

The invention discloses an esophageal adenocarcinoma plasma circulation microbial marker combination, a reagent, a kit, a risk prediction model and application thereof, and belongs to the cross technical field of liquid biopsy and microbiomics. The esophageal adenocarcinoma plasma circulating microbial marker combination disclosed by the invention comprises enterobacteriaceae, cilia, prevotella, ackermania, lactobacillus fermentum and streptococcus. When the esophageal adenocarcinoma plasma circulating microbial marker combination is used for verifying esophageal adenocarcinoma patients and healthy controls, the AUC is 0.952, the sensitivity is 100%, the specificity is 80.00%, the accuracy is 91.43%, the positive predictive value is 86.96%, and the negative predictive value is 100%; the esophageal adenocarcinoma plasma circulating microbial marker combination can effectively distinguish esophageal adenocarcinoma patients from healthy people, is suitable for early screening of esophageal adenocarcinoma, and has remarkable clinical screening application value.

Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg / day.

This invention belongs to the field of cosmetic technology, specifically relating to a composition for skin barrier repair and anti-inflammation after non-surgical cosmetic procedures and its application. The composition comprises Xinjiang comfrey peptide and Xinjiang comfrey naphthoquinone, with a mass ratio of 50-200:1. This composition synergistically inhibits the release of LPS-induced inflammatory factors, alleviating acute inflammatory reactions such as redness and burning after cosmetic procedures, achieving a dual effect of anti-inflammation and repair. The composition significantly reduces postoperative inflammatory redness and improves discomfort symptoms such as dryness and stinging. Through a multi-target mechanism, this invention solves the technical problems of existing repair products having single functions and slow onset of action, providing a highly efficient and comprehensive repair solution for skin after cosmetic procedures.

The invention relates to a construction method of a thyroid-related eye disease animal model, and belongs to the technical field of biology. The invention provides a thyroid-associated ophthalmopathy animal model construction method, which comprises: (1) separating and purifying in vitro peripheral blood collected from a thyroid-associated ophthalmopathy patient to obtain an exosome; and (2) injecting the exosome into a to-be-modeled animal to prepare the thyroid-associated ophthalmopathy animal model. According to the invention, exosomes are extracted from in-vitro peripheral blood of patients with thyroid-associated ophthalmopathy and are injected into animals, so that the thyroid-associated ophthalmopathy animal model with a plurality of pathological characteristics such as orbital tissue inflammatory response, fibrosis, orbital lesion, thyroid dysfunction and the like is successfully constructed; the method can be widely applied to pathological mechanism research of thyroid-related eye diseases and screening and evaluation of thyroid-related eye disease treatment drugs.

The present disclosure relates to flavor compositions and pet food products for preventing and / or treating chronic kidney disease (CKD) and / or urinary tract disease in an animal. In certain embodiments, the flavor compositions and pet food products have enhanced palatability.

There is a provided a urine collection device for collecting an uncontaminated urine sample from a pre-continent or an incontinent user, the urine collection device comprising: a receptacle configured to be placed within a nappy or an incontinence pad of the user to receive and retain a urine sample collected from the user in use, wherein the receptacle comprises: a receiving portion for receiving the urine sample, the receiving portion comprising an opening configured to engage with a human body portion surrounding external genitalia of the user, thereby enabling urine exiting the body of the user to be captured directly in use; a reservoir for retaining the received urine sample in use; and an outlet for draining the retained urine sample in use, wherein the opening is larger than the outlet.

The invention belongs to the technical field of gestational diabetes diagnosis marker screening, and particularly relates to a biomarker for predicting or diagnosing gestational diabetes and application of the biomarker. The invention discloses a biomarker for predicting or diagnosing gestational diabetes mellitus, the biomarker is selected from one or more of hypoxanthine, cortisol, dihydrotachysterol and cycloleucine, and more preferably, the biomarker comprises hypoxanthine, cortisol, dihydrotachysterol, (3R, 4R)-D-ketolactone, creatine, cycloleucine and L-hydroorotic acid. The seven biomarkers disclosed by the invention can predict or diagnose gestational diabetes mellitus independently or jointly through plasma detection at the early pregnancy stage, effectively improve the early diagnosis rate of gestational diabetes mellitus and improve disease prognosis, and have clinical use and popularization values.

The invention discloses an early diagnosis marker for B-cell lymphoma, a cross-species screening method based on lamprey and application, and relates to the technical field of molecular diagnosis. In the prior art, tissue biopsy is strong in invasiveness, and a traditional marker is low in early detection rate; in order to solve the problems that a large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large-scale large- When the expression quantity of the gene in a sample is greater than or equal to 1.8 times of that of a normal B cell (HMY2. CIR), the lymphoma is judged to be positive, and the minimally invasive early diagnosis efficiency is remarkably improved.

Disclosed herein is a urine collection bag, system, and methods directed to automated measurement of a quantity of urine. The urine collection system can include the urine collection bag, a catheter, and flexible drainage tubing. The urine collection bag can include a collection area, force sensors, and circuitry configured to determine the volume of urine in the collection area based on pressure or weight measured by the force sensors, and the specific gravity of the urine. The catheter may include a small female external catheter (FEC) with an opening on a top side, a wicking catheter with a wicking area on a top side, a finger-mountable catheter, or a male external catheter (MEC). The tubing may be secured to a patient's leg with a stabilization device or a fabric strap. The catheter can remain on a patient while the patient stands or walks.

An incontinence article for a male that has a penis and a scrotum extends along a longitudinal axis. The article has a pouch and a sling that is connected to that pouch. The pouch includes one or more layers of nonwoven material and is configured to envelop the penis, with the pouch having a first open end and a second closed end that is longitudinally opposed the first open end. The sling is connected to the pouch adjacent the first open end of the pouch and includes a loop portion that is configured to fit around an underside of the scrotum and the penis of the male, with that loop portion being extensible in at least a generally circumferential direction of the loop portion.

The invention relates to a urine specific protein detection sample quality screening system and screening method. The screening method comprises the following steps: firstly, creating a urine specific protein quality model; then collecting an image of a to-be-detected sample; and finally, analyzing and evaluating the sample to be detected according to the sample quality model and the image of the sample to be detected, and converting urine colors (such as light yellow, deep yellow, hematuria and the like) into quantifiable numerical values by collecting the image of the sample (urine). Compared with traditional naked eye observation, judgment deviation caused by subjective factors such as experience and ambient light of detection personnel is avoided, and the detection result is more objective and repeatable; according to the method, the sample image is converted into quantifiable numerical values so as to carry out numerical analysis on the detection data of the color, clarity and turbidity of the sample, hematuria and urine with high turbidity in the sample are automatically screened out, manual operation steps are reduced, the detection efficiency is improved, and the method is particularly suitable for clinical or large-scale screening scenes.

The present application provides a urine processing method and a urine testing system. The method comprises processing urine to obtain urinary sediment and supernatant, performing crystallization processing on the supernatant and making analysis to obtain supernatant-related parameters, and making comprehensive analysis through combination of the supernatant-related parameters with urinary sediment-related parameters and urine dry chemistry-related parameters. The system comprises a urine processing module configured to process urine to obtain urinary sediment and supernatant, and a supernatant analysis module configured to perform crystallization processing on the supernatant and make analysis to obtain supernatant-related parameters, and to make comprehensive analysis through combination of the supernatant-related parameters with the urinary sediment-related parameters and the urine dry chemistry-related parameters.

The invention includes methods of preventing or treating acute lung injury using a MAP3K2 / MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.